Inhibition of cyclophosphamide mutagenicity by beta-carotene

Biomed Pharmacother. 1985;39(8):445-8.

Abstract

Cyclophosphamide (CP) metabolites, rather than the parent compound, show mutagenic activity towards Salmonella typhimurium TA 1535 tester strain when S9 fraction from phenobarbital (PB)-induced rat liver is used as in vitro metabolizing system. On the other hand, inhibition of CP in vitro mutagenicity was observed by adding increasing amounts of beta-carotene (beta-C) to the system. A typical dose-dependent mutagenic response was observed by assaying 24 h urine samples of PB-induced rats injected i.p. with different amounts of CP. Addition of beta-C to urines of CP-treated rats failed to inhibit their mutagenicity. Conversely, a marked decrease in urine mutagenicity was observed when rats were simultaneously treated with the two drugs. These data show that beta-carotene partially inhibits, in vitro and in vivo, CP metabolism via hepatic mixed-function oxidase enzymes to mutagenic species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biotransformation
  • Carotenoids / pharmacology*
  • Cyclophosphamide / antagonists & inhibitors*
  • Cyclophosphamide / toxicity
  • Cyclophosphamide / urine
  • In Vitro Techniques
  • Liver / metabolism
  • Mutagenicity Tests
  • Phenobarbital / pharmacology
  • Rats
  • Rats, Inbred Strains
  • Salmonella typhimurium / drug effects
  • beta Carotene

Substances

  • beta Carotene
  • Carotenoids
  • Cyclophosphamide
  • Phenobarbital